This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NOVATO, Calif., July 28, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release second quarter 2014 financial results after market close on Thursday, August 7, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (877) 870-4263 for domestic callers or (412) 317-0790 for international callers. A live webcast of the conference call will be available online from the investor relations section of the company website at
www.raptorpharma.com . After the call, a webcast replay will be available on the Raptor website. A telephone replay of the call will be available by dialing (877) 344-7529 for domestic callers or (412) 317-0088 for international callers, and conference number: 10050369.
About Raptor Pharmaceuticals
Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), and Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. A request for EU orphan designation for RP103 in HD has been submitted. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit
CONTACT: COMPANY CONTACT:
Chief Financial Officer
Raptor Pharmaceutical Corp.
Westwicke Partners, LLC
Robert H. Uhl